P/E ratio for Cocrystal Pharma (COCP)
P/E ratio as of May 2024 (TTM): -0.6769
According to Cocrystal Pharma 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.676856. At the end of 2022 the company had a P/E ratio of -0.4097.
P/E ratio history for Cocrystal Pharma from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.4097 | -99.16% |
| 2021 | -48.8 | 545.22% |
| 2020 | -7.56 | 2181.78% |
| 2019 | -0.3311 | -83.9% |
| 2018 | -2.06 | -98.97% |
| 2017 | -200 | 5701.85% |
| 2016 | -3.45 | -67.9% |
| 2015 | -10.7 | -51.89% |
| 2014 | -22.3 | 84.43% |
| 2013 | -12.1 | -50.61% |
| 2012 | -24.5 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.3 | -1,616.62% | 🇺🇸 USA |
 Merck MRK | 70.9 | -10,580.00% | 🇺🇸 USA |
 Nature's Sunshine Products NATR | 68.3 | -10,193.79% | 🇺🇸 USA |
 USANA USNA | 13.4 | -2,076.95% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.